All posts in Updated Retinal Bulletin


POT-4 is a derivative of Compstatin, a peptide that inhibits complement activation. Complement activation plays a significant role in the cause of AMD. POT-4 is initially being developed for treatment of AMD. Potentia Pharmaceuticals, Inc. is beginning Phase I clinical trials in Tucson and Miami.


Nutrition for the Well-Being of the Eye

Omega 3 fatty acids have been shown to increase the general sense of well-being and promote high health. They are present in fish and are highest in mackerel, white fish, tuna, and salmon.

Zinc has a specific role in the normal functioning of photoreceptors in the eye. Zinc is found in high protein foods such as beef, pork, and whole grain cereals.

Recently, it has been suggested that the carotenoids, Lutein (pronounced loo-teen) and Zeaxanthin (pronounced zee-uh-zan-thin) play an important role in eye health.

In the Eye Disease Case Control Study, medical researchers found that individuals experienced a significantly lower risk for developing age related macular degeneration when they had high amounts of Lutein and Zeaxanthin in their blood.

Sources of Lutein include yellow peppers, mango, blueberries, and green leafy vegetables such as kale, spinach, chard, and broccoli. Sources of Zeaxanthin include orange sweet peppers, broccoli, corn, lettuce, spinach, tangerines, oranges, and eggs.


Testing a New Long Acting Drug for Wet Age Related Macular Degeneration

Regeneron Pharmaceuticals, Inc., will be testing the investigational drug, VEGF Trap, in a Phase III clinical trial. VEGF Trap is a human Fc-fusion protein that binds and blocks VEGF in the retina when injected intravitreally. VEGF Trap may prove to be a long acting therapy since it is able to more potently bind VEGF than currently available anti-VEGF therapies. This trial will compare VEGF Trap to Lucentis.